Guest guest Posted March 24, 2009 Report Share Posted March 24, 2009 SkyePharma files key asthma drug for FDA approval - SkyePharma Plc (SKP.L) has submitted its asthma drug Flutiform for approval with the U.S. Food and Drug Administration, bringing the medicine's commercialisation a step nearer. If approved, Flutiform will be the third fixed-dose asthma combination drug on sale in the United States, after GlaxoKline Plc's (GSK.L) market-leading Advair and AstraZeneca Plc's (AZN.L) Symbicort. The market for asthma treatments is about to get tougher, with the potential entry of generic versions of Advair and Symbicort, and the arrival of next-generation therapies. But SykePharma is optimistic there is still a valuable niche for Flutiform. http://www.reuters.com/article/rbssHealthcareNews/idUSLN26983820090323 Alana Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.